2.50
Hdl Handle:
http://hdl.handle.net/10755/165057
Category:
Abstract
Type:
Presentation
Title:
SWEET'S SYNDROME
Author(s):
Martin, Jennifer
Author Details:
Jennifer Martin, RN BSN OCN, John's Hopkins Hospital, Baltimore, Maryland, USA, email: jmarti93@jhmi.edu
Abstract:
SweetÆs syndrome, otherwise known as acute febrile neutrophilic dermatosis, is a rare disorder and potential complication of G-CSF administration. Though the disease pathophysiology is not entirely understood, an underlying neutrophil-mediated hypersensitivity reaction is believed to play a central role. Approximately 20-25% of patients with Sweet's syndrome have an underlying, typically hematologic malignancy. Sweet's syndrome management poses unique practice issues for the oncology nurse. This presentation will educate nurses in the clinical presentation, identification and management of Sweet's syndrome by looking at different case studies. Early identification, intervention and treatment applications are necessary to effectively heal the patient while diminishing their risk for infection and controlling pain. The nursing care matrix includes early identification of lesion manifestations, ensuring appropriate dermatological and wound care consults, administration of suitable treatments and symptom management. While standard medication therapy is corticosteroids, other documented effective treatments include potassium iodide, dapsone, indomethacin, colchicine, and cyclosporine. Skin biopsy confirms the diagnosis of Sweet's syndrome, with rapid improvement in both symptoms and dermatological abnormalities after initiation of systemic steroid therapy. Antibiotic treatment proves ineffective; therefore proper diagnosis is critical for appropriate patient management. Appropriate wound care performed by nursing is imperative to preventing infection. Pain control also remains a priority in these patients. Early identification of this rare complication and appropriate treatment applications are key in managing Sweet's syndrome. Monitoring infectious complications, effective pain management interventions and the administration and response to the poly-pharmaceuticals are important nursing outcome measures that will facilitate treatment planning and recovery. The implications of SweetÆs syndrome for oncology nurses are significant. While administration of corticosteroid therapy in malignancy- associated SweetÆs syndrome often promptly resolves symptoms and lesions, early identification is important. In addition, identification of SweetÆs syndrome recurrences could also be indicative of recurrence of the malignancy. It is necessary to distinguish SweetÆs syndrome from other skin disorders, such as herpes simplex and varicella zoster viruses or leukemia cutis, to avoid unnecessary use of antimicrobial or other therapies. Sweet's syndrome practice findings must be added to the growing body of oncology nursing symptom management evidence to guide further nursing practice.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2007
Conference Name:
32nd Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Las Vegas, Nevada, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleSWEET'S SYNDROMEen_GB
dc.contributor.authorMartin, Jenniferen_US
dc.author.detailsJennifer Martin, RN BSN OCN, John's Hopkins Hospital, Baltimore, Maryland, USA, email: jmarti93@jhmi.eduen_US
dc.identifier.urihttp://hdl.handle.net/10755/165057-
dc.description.abstractSweetÆs syndrome, otherwise known as acute febrile neutrophilic dermatosis, is a rare disorder and potential complication of G-CSF administration. Though the disease pathophysiology is not entirely understood, an underlying neutrophil-mediated hypersensitivity reaction is believed to play a central role. Approximately 20-25% of patients with Sweet's syndrome have an underlying, typically hematologic malignancy. Sweet's syndrome management poses unique practice issues for the oncology nurse. This presentation will educate nurses in the clinical presentation, identification and management of Sweet's syndrome by looking at different case studies. Early identification, intervention and treatment applications are necessary to effectively heal the patient while diminishing their risk for infection and controlling pain. The nursing care matrix includes early identification of lesion manifestations, ensuring appropriate dermatological and wound care consults, administration of suitable treatments and symptom management. While standard medication therapy is corticosteroids, other documented effective treatments include potassium iodide, dapsone, indomethacin, colchicine, and cyclosporine. Skin biopsy confirms the diagnosis of Sweet's syndrome, with rapid improvement in both symptoms and dermatological abnormalities after initiation of systemic steroid therapy. Antibiotic treatment proves ineffective; therefore proper diagnosis is critical for appropriate patient management. Appropriate wound care performed by nursing is imperative to preventing infection. Pain control also remains a priority in these patients. Early identification of this rare complication and appropriate treatment applications are key in managing Sweet's syndrome. Monitoring infectious complications, effective pain management interventions and the administration and response to the poly-pharmaceuticals are important nursing outcome measures that will facilitate treatment planning and recovery. The implications of SweetÆs syndrome for oncology nurses are significant. While administration of corticosteroid therapy in malignancy- associated SweetÆs syndrome often promptly resolves symptoms and lesions, early identification is important. In addition, identification of SweetÆs syndrome recurrences could also be indicative of recurrence of the malignancy. It is necessary to distinguish SweetÆs syndrome from other skin disorders, such as herpes simplex and varicella zoster viruses or leukemia cutis, to avoid unnecessary use of antimicrobial or other therapies. Sweet's syndrome practice findings must be added to the growing body of oncology nursing symptom management evidence to guide further nursing practice.en_GB
dc.date.available2011-10-27T12:11:45Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:11:45Z-
dc.conference.date2007en_US
dc.conference.name32nd Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationLas Vegas, Nevada, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.